Taking advantage of new kinds of neural network models to accelerate drug discovery
GlaxoSmithKline is a pharmaceutical company dedicated to improving the quality of human life by helping people do more, feel better, and live longer. Innovation is at the core of their mission and in order to take advantage of new kinds of neural network models for drug discovery, they realized they needed an AI solution with larger memory and throughput. With a CS-1 system, they are increasing the complexity of their models, while decreasing training time by 80x.
SVP Global Head of AI and ML @ GlaxoSmithKline
Kim Branson, SVP Global Head of AI and ML at GSK, discusses AI for drug discovery and the Cerebras partnershipWatch Now